title: [Tricyclic antidepressants and monoamine oxidase inhibitors - do they still have a role in the treatment of depression?].
abstract: Today, tricyclic antidepressants and MonoAmine Oxidase Inhibitors are prescribed less frequently compared to Selective Serotonin Reuptake Inhibitors (SSRIs) or selective serotonin and noradrenalin reuptake inhibitors. These new medications are associated with a better safety profile. The new generation of psychiatrists is not really comfortable with these old medications. However, their use is still justified in some cases of treatment resistance, in the treatment of some anxious disorders, and in the management of chronic pain. But, their prescription requires a good knowledge of the potential complications.
authors.affiliation: Service de Psychiatrie et de Psychologie Médicale, CHU de Liège, Belgique.
authors.forename: W
authors.initials: W
authors.lastname: Pitchot
authors.forename: G
authors.initials: G
authors.lastname: Scantamburlo
authors.forename: M
authors.initials: M
authors.lastname: Ansseau
mesh_terms: D000929:Antidepressive Agents, Tricyclic / Q000494:pharmacology / Q000627:therapeutic use*; D003863:Depression / Q000188:drug therapy*; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000929:Antidepressive Agents, Tricyclic; D008996:Monoamine Oxidase Inhibitors